Danaher Corporation (DHR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Danaher Corporation (DHR) Healthcare & Pipeline Overview

Danaher Corporation is a diversified science and technology company providing innovative solutions in life sciences, diagnostics, and environmental & applied solutions. With a focus on high-growth markets and a disciplined acquisition strategy, Danaher leverages its proprietary Danaher Business System to drive operational efficiencies and market leadership.

What Is the Investment Thesis for DHR?

Danaher Corporation presents a notable research candidate due to its diversified business model, strong market positions, and consistent execution through the Danaher Business System. With a market capitalization of $148B and a profit margin of 14.9%, Danaher demonstrates financial stability and profitability. Key value drivers include continued growth in the life sciences and diagnostics segments, driven by increasing demand for advanced healthcare solutions. The company's disciplined acquisition strategy and focus on operational efficiencies are expected to further enhance profitability and shareholder value. The dividend yield of 0.79% provides a modest income stream, while potential risks include regulatory changes and economic slowdowns impacting healthcare spending.

Based on FMP financials and quantitative analysis

DHR Key Highlights

Market Cap of $148B reflects Danaher's strong market position and investor confidence.

• P/E ratio of 36.62 indicates a premium valuation, reflecting expectations of future growth.
• Gross Margin of 60.7% demonstrates efficient operations and strong pricing power.
• Profit Margin of 14.9% showcases Danaher's ability to convert revenue into profit.
• Beta of 0.99 suggests that Danaher's stock price is slightly less volatile than the overall market.

Who Are DHR's Competitors?

DHR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are DHR's Key Strengths?

Diversified business model with exposure to multiple high-growth markets.

• Strong market positions in life sciences, diagnostics, and environmental solutions.
• Proprietary Danaher Business System (DBS) drives continuous improvement and operational excellence.
• Proven track record of successful acquisitions.

What Are DHR's Weaknesses?

Exposure to regulatory changes and healthcare spending trends.

• Dependence on innovation and technological advancements.
• Integration risks associated with acquisitions.
• Potential for economic slowdowns to impact demand.

What Could Drive DHR Stock Higher?

DHR catalyst: Continued implementation of the Danaher Business System (DBS) across all segments to drive operational efficiencies and margin expansion.

• Strategic acquisitions to expand product portfolio and market reach in high-growth areas.
• New product launches and technological advancements in genomics, diagnostics, and environmental solutions.
• Expansion in emerging markets with growing healthcare needs and increasing demand for water quality solutions.

What Are the Key Risks for DHR?

Rich valuation — a P/E of 36.62 runs well above the Healthcare sector’s ~21.60x, leaving little room for a miss.

• Regulatory changes and healthcare spending trends impacting demand for Danaher's products and services.
• Integration risks associated with acquisitions and the potential for disruptions to business operations.
• Competition from other large healthcare and industrial companies.
• Economic downturns and global health crises impacting demand and supply chains.

What Are the Growth Opportunities for DHR?

• Expansion in Genomics and Bioprocessing: Danaher can capitalize on the rapidly growing genomics and bioprocessing markets. The global genomics market is projected to reach $55.4 billion by 2028, driven by advancements in DNA sequencing and personalized medicine. Danaher's Life Sciences segment, with its strong portfolio of genomics consumables and bioprocess technologies, is well-positioned to capture a significant share of this market. Investing in R&D and strategic acquisitions in this area will be crucial for sustained growth.
• Increasing Demand for Diagnostics Solutions: The global diagnostics market is expected to grow, driven by the increasing prevalence of chronic diseases and the need for early and accurate diagnosis. Danaher's Diagnostics segment offers a comprehensive range of clinical instruments, reagents, and software for hospitals, laboratories, and physicians' offices. Expanding its presence in emerging markets and developing innovative diagnostic solutions will be key to capturing this growth opportunity. The market is projected to reach $127.78 billion by 2029.
• Water Quality and Treatment Solutions: With increasing concerns about water scarcity and pollution, the demand for water quality and treatment solutions is growing. Danaher's Environmental & Applied Solutions segment provides instrumentation, software, and services for water analysis and treatment. Expanding its product offerings and geographic reach in this area will be crucial for capturing this growth opportunity.
• Danaher Business System (DBS) Implementation: Danaher's proprietary Danaher Business System (DBS) is a key competitive advantage that drives continuous improvement and operational excellence across its businesses. Expanding the implementation of DBS across all segments and newly acquired companies will further enhance profitability and efficiency. This ongoing process optimization will contribute to sustained growth and shareholder value.
• Strategic Acquisitions: Danaher has a proven track record of successful acquisitions that have expanded its product portfolio and market reach. Continuing to pursue strategic acquisitions in high-growth areas, such as genomics, diagnostics, and environmental solutions, will be crucial for sustained growth. A disciplined approach to acquisitions, with a focus on companies that align with Danaher's strategic priorities and can benefit from DBS, will be essential.

What Are DHR's Competitive Advantages?

• Proprietary Danaher Business System (DBS) drives continuous improvement and operational excellence.
• Diversified portfolio of leading brands with strong market positions.
• Strategic acquisition strategy expands product portfolio and market reach.
• Focus on high-growth markets, such as genomics, diagnostics, and environmental solutions.

What Does DHR Do?

Danaher Corporation, founded in 1969 and headquartered in Washington, D.C., has evolved from Diversified Mortgage Investors, Inc. into a global leader in science and technology. The company operates through three primary segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of products including mass spectrometers, flow cytometry systems, microscopes, and genomic consumables, serving pharmaceutical, biopharmaceutical, and research institutions. The Diagnostics segment provides clinical instruments, reagents, and software for hospitals, laboratories, and physicians' offices, focusing on chemistry, immunoassay, and molecular diagnostics. The Environmental & Applied Solutions segment delivers instrumentation, software, and services for water quality analysis and treatment, as well as packaging and color management solutions for various industries. Danaher's success is underpinned by the Danaher Business System (DBS), a proprietary set of tools and processes that drive continuous improvement and operational excellence across its businesses. Through strategic acquisitions and organic growth, Danaher has built a diversified portfolio of leading brands, each focused on delivering innovative solutions to its customers.

What Products and Services Does DHR Offer?

• Develops and manufactures professional, medical, industrial, and commercial products.
• Offers solutions for life sciences research, including genomics, proteomics, and cell biology.
• Provides diagnostic instruments, reagents, and software for clinical laboratories and healthcare providers.
• Delivers water quality analysis and treatment solutions for residential, commercial, and industrial applications.
• Offers packaging and color management solutions for consumer, pharmaceutical, and industrial products.
• Serves customers worldwide through a diversified portfolio of leading brands.

How Does DHR Make Money?

• Develops and manufactures a wide range of products and services across three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions.
• Generates revenue through the sale of instruments, reagents, consumables, software, and services.
• Utilizes the Danaher Business System (DBS) to drive continuous improvement and operational excellence.
• Pursues strategic acquisitions to expand its product portfolio and market reach.

What Industry Does DHR Operate In?

Danaher operates in the healthcare and industrial sectors, which are characterized by continuous innovation and increasing demand for advanced technologies. The global diagnostics market is expected to grow, driven by the increasing prevalence of chronic diseases and the need for early and accurate diagnosis. The life sciences sector is also experiencing growth, fueled by advancements in genomics, proteomics, and cell biology. Danaher's diversified portfolio and strong market positions enable it to capitalize on these trends, while competition from companies like Amgen Inc. (AMGN) and Pfizer Inc. (PFE) requires continuous innovation and operational excellence.

Who Are DHR's Key Customers?

• Pharmaceutical and biopharmaceutical companies.
• Hospitals, physicians' offices, and reference laboratories.
• Universities, medical schools, and research institutions.
• Various industrial manufacturers.
• Residential and commercial customers requiring water quality solutions.

Company Profile

Danaher Corporation operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Washington, US. The company is led by CEO Rainer Blair. DHR has traded publicly since 1978.

Danaher Corporation Financial Trajectory

Danaher Corporation (DHR) reported $6.26B in revenue for Q2 FY2026, reflecting 5.3% growth compared to the prior quarter. The company recorded net income of $870.0M, with diluted EPS of $1.23. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, DHR averaged $1.41 in diluted EPS.

How Danaher Corporation Is Valued

Danaher Corporation carries a market capitalization of $148B, placing it in the large-cap category. Analyst price targets span from $195.00 to $249.00, with a consensus of $221.58. At the current price of $211.20, that implies approximately 5% upside potential. Relative to its peer group, DHR's quantitative score of 64/100 is roughly in line with the peer average of 67/100.

Return on equity for Danaher Corporation stands at 7.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.4%, showing how much profit it generates from its asset base. DHR trades at a trailing price-to-earnings ratio of 36.62, above the Healthcare sector average of ~21.60x. Its free cash flow yield is 3.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.87 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.7%, the inverse of the P/E and a quick read on earnings relative to price.

Danaher Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.52 places it in the safe zone, indicating low near-term bankruptcy risk.

Danaher Corporation has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 7.3% above estimates on average.

Over the past six months, Danaher Corporation insiders filed 30 SEC Form 4 transactions — 8 sales and 22 purchases. On net that is roughly 3.5M shares acquired (about $474.7M) — insiders putting money in tends to read as conviction.

DHR Financials

Next earnings report: Oct 20, 2026

DHR earnings history & estimates →

DHR Latest News

DHR Analyst Consensus

DHR MoonshotScore

Latest Danaher Corporation Analysis

DHR Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources